Study status | Drug | Drug class | Intervention | Primary outcome | N | Follow-up (years) | Start and end date | Clinicaltrials.gov ID | |
---|---|---|---|---|---|---|---|---|---|
CANVAS program | Completed | Canagliflozin | SGLT-2 Inhibitor | Canagliflozin 100 mg vs. canagliflozin 300 mg vs. placebo | CV death, MI, or stroke | 10,142 | 3.6 | 12.2009–02.2017 | NCT01032629 |
EXSCEL | Completed | Exenatide | GLP-1 receptor agonist | Exenatide once-weekly vs. placebo | CV death, MI, or stroke | 14,752 | 3.2 | 06.2010–04.2017 | NCT01144338 |
DEVOTE | Completed | Insulin degludec | Basal insulins | Insulin degludec vs. Insulin glargine | CV death, MI, or stroke | 7637 | 2.0 | 10.2013–10.2016 | NCT01959529 |
ACE | Completed | Acarbose | α-glucosidase inhibitor | Acarbose vs. placebo | CV death, MI, or stroke, HHF,HUA | 6522 | 5.0 | 02.2009–04.2017 | NCT00829660 |
FOURIER | Completed | Evolocumab | PCSK9 inhibitor | Evolocumab vs. placebo | CV death, MI, stroke, UA or coronary revascularisation | 27,564 | 2.2 | 01.2013–11.2016 | NCT01764633 |